KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma

The potential clinical impact of KRAS and epidermal growth factor receptor (EGFR) mutations has been investigated in lung adenocarcinomas; however, their prognostic value remains controversial. In our study, we sought to investigate the prognostic significance of driver mutations using a large cohort of early-stage lung adenocarcinomas. We reviewed patients with pathologic early-stage, lymph node-negative, solitary lung adenocarcinoma who had undergone surgical resection (1995 to 2005; stage I/II = 463/19). Tumors were classified according to the IASLC/ATS/ERS classification and genotyped by Sequenom MassARRAY system and polymerase chain reactionbased assays. In stage I disease, the Kaplan-Meier method and cumulative incidence of recurrence analyses were used to estimate the probability of overall survival (OS) and recurrence, respectively. Of all, 129 (27%) patients had mutations in KRAS, 86 (18%) in EGFR, 8 (2%) in BRAF, 8 (2%) in PIK3CA, 4 (1%) in NRAS, and 1 (0.2%) in AKT1. EGFR L858R mutation correlated with lepidic predominant histology (P = 0.006), whereas exon 19 deletion correlated with acinar predominant histology (P < 0.001). EGFR mutations were not detected in invasive mucinous adenocarcinomas (P = 0.033). The 5-year OS of patients with KRAS-mutant tumors was significantly worse (n = 124; 5-year OS, 63%) than those with KRAS wild-type (n = 339; 77%; P < 0.001). In solid predominant tumors, KRAS mutations correlated with worse OS (P = 0.008) and increased risk of recurrence (P = 0.005). On multivariate analysis, KRAS mutation was an independent prognosticator of OS in all patients (hazard ratio, 1.87; P < 0.001) and recurrence in solid predominant tumors (hazard ratio, 4.73; P = 0.012). In patients with resected stage I lung adenocarcinomas, KRAS mutation was an independent prognostic factor for OS and recurrence, especially in solid predominant tumors.